Genetic testing of your liver enzymes and other genes will give an idea of how quickly you will break down some antidepressant and antipsychotic medications, whether you might need a different dose than most people, and your likelihood of getting some side effects.

Beginning on November 10, 2014, patients enrolled in the IMPACT study will have their genes tested using Assurex Health proprietary technology, GeneSight® Psychotropic.

The switch to GeneSight testing is a result of the CAMH-Assurex Health partnership agreement. The goal of this agreement is to bring the benefits of a personalized approach to psychiatric treatment to more Canadians.
Click here to learn more about the partnership.

The GeneSight® Psychotropic test analyzes how eight genes may affect a patient’s metabolism and their response to 33 antidepressant and antipsychotic medications approved by Health Canada. The expanded GeneSight report includes information on the same genes, antidepressant and antipsychotic medications that were available on the CAMH Pharmacogenetics report.

If you would like more details on the GeneSight® Psychotropic test, or to learn how you can register to receive the GeneSight® Psychotropic reports for your IMPACT patients, please contact the Assurex Health IMPACT Team at www.im-pact.ca or Canada.Clinical@assurexhealth.com. We look forward to hearing from you!

TORONTO – November 19, 2013 – The Centre for Addiction and Mental Health (CAMH), Canada’s leading hospital for mental health, and Assurex Health, a global leader in personalized medicine, have signed an agreement for a joint venture to bring the benefits of this treatment approach to more Canadians.
The personalized approach helps to match the right medication at the right dose for each patient, based on their genetic makeup. Using Assurex Health’s GeneSight panel, physicians can easily see which psychiatric medications are likely to be effective for each patient and which ones are not, often avoiding treatment failure and side effects. CAMH